Prediction: These 2 Obesity Drug Stocks Could Double in 2026

The article highlights two obesity-drug stocks, Viking Therapeutics and AbbVie, as potential double candidates on promising clinical progress and a market expected to approach $100 billion by the end of the decade. Viking’s VK-2735 and AbbVie’s ABBV-295 both showed encouraging trial data, including Viking’s earlier 121% one-day surge after phase 2 results and AbbVie’s 7% to 9% weight-loss range in phase 1 dosing. The piece is largely bullish commentary rather than hard news, but it could support sentiment in the obesity drug and biotech subsector.

Analysis

The market is still pricing obesity as a single-product, GLP-1 winner-take-most story, but the next leg is likely to come from differentiation rather than just efficacy. That creates a second-order shift: large-cap pharma with existing sales forces, payer access, and multiple launch vectors can monetize obesity with less balance-sheet risk than single-asset biotech, while the pure plays remain event-driven trading vehicles. VKTX is the higher beta expression because any incremental trial success can re-rate the company before commercial execution matters, but that also means valuation is highly dependent on clean data and continued capital-market appetite.

The more interesting setup is ABBV as a portfolio hedge on the obesity theme. If amylin proves clinically usable, it addresses the two issues that can cap GLP-1 adoption: tolerability and persistence, which would expand the addressable market instead of just stealing share. Even a modest obesity franchise would matter because it layers onto an already scaled earnings base, so the stock can rerate on option value without needing the asset to become a category leader.

The main risk is that obesity expectations are becoming self-reinforcing into catalyst dates, which inflates short-term implied volatility and leaves both names vulnerable to underwhelming data, trial design issues, or simply slower-than-expected progression into later-stage studies. For VKTX, the stock can gap violently in either direction around readouts; for ABBV, the risk is slower disappointment rather than a single binary event, making it a better vehicle for medium-term accumulation. The consensus may be underestimating how much of the next wave will be about patient persistence, oral convenience, and combination regimens rather than raw weight-loss percentages.

Key Decisions for Investors

• Long ABBV vs. VKTX pair trade over the next 3-6 months: ABBV offers lower trial-binary risk and a cleaner valuation anchor, while VKTX is exposed to sharp downside if obesity data are merely good rather than exceptional.
• Buy VKTX upside exposure via call spreads into the next data window, not outright shares: use a defined-risk structure to capture a potential catalyst-driven re-rate while limiting gap risk if results disappoint.
• Add ABBV on weakness as a medium-term compounder with embedded obesity optionality: thesis works over 6-12 months if the market starts valuing pipeline optionality rather than just current earnings multiple.
• Sell near-dated VKTX implied volatility into catalyst strength if the stock runs ahead of data: the setup is highly path-dependent, and premium collection is attractive when event premiums become disconnected from base-case probabilities.
• Avoid chasing the broad obesity basket indiscriminately; prefer a barbell of ABBV for durability and VKTX for convexity, rather than owning both as if they have similar risk profiles.